Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ribavirin monotherapy for chronic hepatitis C.

J Brok1, L L Gluud, C Gluud

  • 1Centre for Clinical Intervention Research, Copenhagen University Hospital, Copenhagen Trial Unit, Department 7102, H:S Rigshospitalet, Blegdamsvej 9, Copenhagen, Denmark 2100 Ø. jbrok@ctu.rh.dk

The Cochrane Database of Systematic Reviews
|October 20, 2005
PubMed
Summary

Ribavirin monotherapy for chronic hepatitis C showed no significant benefit for virological response or liver morbidity compared to placebo. However, it transiently improved biochemical and histological markers but increased anemia risk, leading to no recommendation outside trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adherence to Protocol Recommendations for Children With Wilms Tumour in Two Consecutive Studies in the United Kingdom and Ireland-Does Variation Matter?

Pediatric blood & cancer·2026
Same author

The risks of adverse events with venlafaxine for adults with major depressive disorder: a systematic review of randomised clinical trials with meta-analysis and Trial Sequential Analysis.

Epidemiology and psychiatric sciences·2024
Same author

Tramadol for chronic pain in adults: protocol for a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.

Systematic reviews·2023
Same author

Risk factors associated with nausea and vomiting in children with cancer receiving chemotherapy.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2022
Same author

Fifty years of clinical and research studies for childhood renal tumors within the International Society of Pediatric Oncology (SIOP).

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Effect of metformin and insulin vs. placebo and insulin on whole body composition in overweight patients with type 2 diabetes: a randomized placebo-controlled trial.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021

Area of Science:

  • Hepatology
  • Virology
  • Clinical Pharmacology

Background:

  • Chronic hepatitis C is a significant global health issue, causing substantial liver-related morbidity and mortality.
  • The disease often progresses asymptomatically for extended periods.
  • Ribavirin monotherapy has been considered a potential treatment option for select patients.

Purpose of the Study:

  • To evaluate the efficacy and safety of ribavirin monotherapy in patients with chronic hepatitis C.
  • To assess the impact of ribavirin on virological, biochemical, histological outcomes, and overall mortality.

Main Methods:

  • A systematic review and meta-analysis of randomized controlled trials were conducted.
  • Trials compared ribavirin with placebo, no intervention, or interferon up to May 2005.

Related Experiment Videos

  • Primary outcomes included sustained viral RNA loss and liver-related morbidity/mortality; secondary outcomes encompassed treatment response and adverse events.

    • Main Results:

    • Thirteen trials with 594 patients were analyzed; most had low methodological quality.
    • Ribavirin showed no significant effect on sustained or end-of-treatment virological response compared to placebo.
    • While improving biochemical and histological responses transiently, ribavirin significantly increased anemia risk and was inferior to interferon.

    Conclusions:

    • Ribavirin monotherapy does not offer significant virological benefits or reduce liver morbidity in chronic hepatitis C patients.
    • Transient improvements in biochemical and histological markers were observed, alongside a notable increase in anemia.
    • The current evidence does not support the use of ribavirin monotherapy outside of rigorously controlled clinical trials.